Evidence map›Paper›PMID 42136969›Full record

ArticleFarmaceuticos comunitarios2026

Design of a Pharmaceutical Protocol for the Evaluation of Phytotherapeutic Products.

L Parra-Astorgano, R Prats Mas, I Villegas Lama, I Busto Domínguez, C Morales Marrero, M Roig Marín-Yaseli, J López Gil

Abstract read
In one paragraph

Article in Farmaceuticos comunitarios, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

L Parra-AstorganoCommunity Pharmacist (Valladolid, Spain). Assistant Professor of Health Sciences, Faculty of Pharmacy, University of Salamanca. Member of the Pharmaceutical Indication and Medication Use Review Working Groups of SEFAC. Member of the Scientific Committee of SEFAC. Member of the Phytotherapy Commission of SEFAC. España.
R Prats MasCommunity Pharmacist (Dénia, Alicante, Spain). Coordinator of the Phytotherapy Commission of SEFAC. España.
I Villegas LamaAssociate Professor, Department of Pharmacology, Faculty of Pharmacy, University of Seville. Member of the Phytotherapy Commission of SEFAC. España.
I Busto DomínguezPharmacist, Technical Department, Official College of Pharmacists of Pontevedra. Member of the Phytotherapy Commission of SEFAC. España.
C Morales MarreroCommunity Pharmacist (San Cristóbal de La Laguna, Tenerife, Spain). Member of the Phytotherapy Commission of SEFAC. España.
M Roig Marín-YaseliCommunity Pharmacist (María de Huerva, Zaragoza, Spain). Community Pharmacy Representative at the Official College of Pharmacists of Zaragoza. Representative of the Spanish Society of Family and Community Medicine (semFYC). Member of the Phytotherapy Commission of SEFAC. España.
J López GilCommunity Pharmacist (Águilas, Murcia, Spain). Representative for Medicinal Plants and Homeopathy at the Official College of Pharmacists of the Region of Murcia. Board Member of the Spanish Society of Phytotherapy (SEFIT). Member of the Phytotherapy Commission of SEFAC. España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The growing use of phytotherapy and the increasing heterogeneity of available formulations require community pharmacists to critically assess marketed products based on criteria of quality, safety, and efficacy. Objectives: To design an operational protocol to support community pharmacists in the evaluation and decision-making process regarding plant-based products. Methods: A consensus process was conducted by the SEFAC Fitoterapia Commission, involving the development and integration of structured checklists and the selection of open-access data sources. A decision tree was defined, starting from the legal classification, and an analytical framework for product evaluation was established. Finally, a rapid reporting template was designed for use in community pharmacy practice. Results: The resulting protocol provides a structured approach to the evaluation of phytotherapeutic products, organized into five sections and a rapid report. It is based on a sequential assessment of legal classification, scientific evidence, quality, safety, and patient information. Its implementation is supported by official, reliable, and openly accessible databases available to community pharmacists. Conclusions: The proposed protocol facilitates consistent and traceable pharmaceutical decision-making by integrating regulatory and scientific information into a practical and applicable tool for community pharmacy.

Indexed as

Community Pharmacy ServicesPhytotherapyPlant PreparationsHumansPharmacistsPlant PreparationsCommunity Pharmacy ServicesDecision Support TechniquesDietary SupplementsHerbal MedicinePharmacovigilancePhytotherapy

Identifiers

PMID42136969
PMCPMC13169827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.